unique_id,text,json_content,type
7ad547a7-2f2f-4d91-9b80-78e1a2b36596,"Visceral crisis is defined as severe organ dysfunction, as assessed by signs and symptoms, laboratory studies and rapid progression of disease. Visceral crisis is not the mere presence of visceral metastases but implies important organ compromise leading to a clinical indication for the most rapidly efficacious therapy.
Examples: Liver visceral crisis: rapidly increasing bilirubin >1.5x ULN in the absence of Gilbert's syndrome or biliary tract obstruction. Lung visceral crisis: rapidly increasing dyspnoea at rest, not alleviated by drainage of pleural effusion.","{""Statement"": ""Visceral crisis is defined as severe organ dysfunction, as assessed by signs and symptoms, laboratory studies and rapid progression of disease. Visceral crisis is not the mere presence of visceral metastases but implies important organ compromise leading to a clinical indication for the most rapidly efficacious therapy.\nExamples: Liver visceral crisis: rapidly increasing bilirubin >1.5x ULN in the absence of Gilbert's syndrome or biliary tract obstruction. Lung visceral crisis: rapidly increasing dyspnoea at rest, not alleviated by drainage of pleural effusion."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""Expert opinion/n/a"", ""Consensus"": ""97%"", ""Type"": ""Guideline statement"", ""Section"": ""ABC definitions"", ""unique_id"": ""7ad547a7-2f2f-4d91-9b80-78e1a2b36596""}",guideline
bf204810-49d4-487f-8f75-e7e2534c13e5,"Primary endocrine resistance is defined as relapse while on the first 2 years of adjuvant ET, or PD within the first 6 months of first-line ET for ABC, while on ET.
Secondary endocrine resistance is defined as relapse while on adjuvant ET but after the first 2 years, or relapse within 12 months of completing adjuvant ET, or PD >=6 months after initiating ET for ABC, while on ET.","{""Statement"": ""Primary endocrine resistance is defined as relapse while on the first 2 years of adjuvant ET, or PD within the first 6 months of first-line ET for ABC, while on ET.\nSecondary endocrine resistance is defined as relapse while on adjuvant ET but after the first 2 years, or relapse within 12 months of completing adjuvant ET, or PD >=6 months after initiating ET for ABC, while on ET."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""Expert opinion/n/a"", ""Consensus"": ""67%"", ""Type"": ""Guideline statement"", ""Section"": ""ABC definitions"", ""unique_id"": ""bf204810-49d4-487f-8f75-e7e2534c13e5""}",guideline
5d1b34c9-9250-4d7e-a36b-b8c6cec79b38,"Oligometastatic disease is defined as low-volume metastatic disease with limited number and size of metastatic lesions (up to five and not necessarily in the same organ), potentially amenable for local treatment aimed at achieving a complete remission status.","{""Statement"": ""Oligometastatic disease is defined as low-volume metastatic disease with limited number and size of metastatic lesions (up to five and not necessarily in the same organ), potentially amenable for local treatment aimed at achieving a complete remission status."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""Expert opinion/n/a"", ""Consensus"": ""78%"", ""Type"": ""Guideline statement"", ""Section"": ""ABC definitions"", ""unique_id"": ""5d1b34c9-9250-4d7e-a36b-b8c6cec79b38""}",guideline
c3155aba-2835-4bb6-9013-0b0460ea503b,"Patients with multiple chronic conditions are defined as patients with additional comorbidities (e.g. cardiovascular, impaired renal or liver function, autoimmune disease) making it difficult to account for all of the possible extrapolations to develop specific recommendations for care.","{""Statement"": ""Patients with multiple chronic conditions are defined as patients with additional comorbidities (e.g. cardiovascular, impaired renal or liver function, autoimmune disease) making it difficult to account for all of the possible extrapolations to develop specific recommendations for care."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""Expert opinion/n/a"", ""Consensus"": ""100%"", ""Type"": ""Guideline statement"", ""Section"": ""ABC definitions"", ""unique_id"": ""c3155aba-2835-4bb6-9013-0b0460ea503b""}",guideline
5079513b-fd29-4f8f-b80c-072fc03c2d38,"Adequate OFS in the context of ABC
Adequate OFS for ABC premenopausal patients can be obtained through bilateral ovariectomy, continuous use of LHRH agonists or OFA through pelvic RT (the latter is not always effective and therefore is the least preferred option).
If an LHRH agonist is used in this age group, it should usually be given on a q4w basis to optimise OFS.
Efficacy of OFS must be initially confirmed analytically through serial evaluations of serum estradiol, even in the presence of amenorrhoea, especially if an AI is administered.
As all endocrine interventions for premenopausal patients with endocrine-responsive ABC require indefinite OFS, choosing one method over the other requires a balance of the patient's wish for potentially preserving fertility, compliance with frequent injections over a long period of time, risk of inadequate estrogen level suppression and cost.","{""Statement"": ""Adequate OFS in the context of ABC\nAdequate OFS for ABC premenopausal patients can be obtained through bilateral ovariectomy, continuous use of LHRH agonists or OFA through pelvic RT (the latter is not always effective and therefore is the least preferred option).\nIf an LHRH agonist is used in this age group, it should usually be given on a q4w basis to optimise OFS.\nEfficacy of OFS must be initially confirmed analytically through serial evaluations of serum estradiol, even in the presence of amenorrhoea, especially if an AI is administered.\nAs all endocrine interventions for premenopausal patients with endocrine-responsive ABC require indefinite OFS, choosing one method over the other requires a balance of the patient's wish for potentially preserving fertility, compliance with frequent injections over a long period of time, risk of inadequate estrogen level suppression and cost."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""I/A\nII/B\nExpert opinion/B"", ""Consensus"": ""85%\n85%\n85%"", ""Type"": ""Guideline statement"", ""Section"": ""ABC definitions"", ""unique_id"": ""5079513b-fd29-4f8f-b80c-072fc03c2d38""}",guideline
e2d0e273-44ed-49b2-ae4e-754cb6b6d775,"Maintenance therapy: in the context of ABC guidelines, maintenance therapy refers to the continuation of anti-HER2 therapy and/or ET after discontinuation of ChT.","{""Statement"": ""Maintenance therapy: in the context of ABC guidelines, maintenance therapy refers to the continuation of anti-HER2 therapy and/or ET after discontinuation of ChT."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""Expert opinion/n/a"", ""Consensus"": ""100%"", ""Type"": ""Guideline statement"", ""Section"": ""ABC definitions"", ""unique_id"": ""e2d0e273-44ed-49b2-ae4e-754cb6b6d775""}",guideline
5a30796e-1165-4f7f-9fbe-431ae01d22a1,Integrative medicine: complementary and integrative medicine (CIM) represents the use of complementary treatments side by side with conventional approaches in a proper therapeutic environment.,"{""Statement"": ""Integrative medicine: complementary and integrative medicine (CIM) represents the use of complementary treatments side by side with conventional approaches in a proper therapeutic environment."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""Expert opinion/n/a"", ""Consensus"": ""100%"", ""Type"": ""Guideline statement"", ""Section"": ""ABC definitions"", ""unique_id"": ""5a30796e-1165-4f7f-9fbe-431ae01d22a1""}",guideline
4c2bd125-f26b-4e6d-9738-756e69089e3d,"The management of ABC is complex and, therefore, involvement of all appropriate specialties in a multidisciplinary team (including but not restricted to medical, radiation and surgical oncologists, imaging experts, pathologists, gynaecologists, psycho-oncologists, social workers, nurses and palliative care specialists) is crucial.","{""Statement"": ""The management of ABC is complex and, therefore, involvement of all appropriate specialties in a multidisciplinary team (including but not restricted to medical, radiation and surgical oncologists, imaging experts, pathologists, gynaecologists, psycho-oncologists, social workers, nurses and palliative care specialists) is crucial."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""Expert opinion/A"", ""Consensus"": ""100%"", ""Type"": ""Guideline statement"", ""Section"": ""General guidelines"", ""unique_id"": ""4c2bd125-f26b-4e6d-9738-756e69089e3d""}",guideline
d1ca3e93-c0a8-4e0f-9d1a-d0d31b5eb1e4,"From the time of diagnosis of ABC, patients should be offered appropriate psychosocial care, supportive care and symptom-related interventions as a routine part of their care. The approach must be personalised to meet the needs of the individual patient.","{""Statement"": ""From the time of diagnosis of ABC, patients should be offered appropriate psychosocial care, supportive care and symptom-related interventions as a routine part of their care. The approach must be personalised to meet the needs of the individual patient."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""Expert opinion/A"", ""Consensus"": ""100%"", ""Type"": ""Guideline statement"", ""Section"": ""General guidelines"", ""unique_id"": ""d1ca3e93-c0a8-4e0f-9d1a-d0d31b5eb1e4""}",guideline
15eebbed-5855-4757-9bf2-f99936ae8d01,"Following a thorough assessment and confirmation of MBC, the potential treatment goals of care should be discussed. Patients should be told that MBC is incurable but treatable, and that some patients can live with MBC for extended periods of time (many years in some circumstances).
This conversation should be conducted in the accessible language, respecting patient privacy and cultural differences, and whenever possible, written information should be provided.","{""Statement"": ""Following a thorough assessment and confirmation of MBC, the potential treatment goals of care should be discussed. Patients should be told that MBC is incurable but treatable, and that some patients can live with MBC for extended periods of time (many years in some circumstances).\nThis conversation should be conducted in the accessible language, respecting patient privacy and cultural differences, and whenever possible, written information should be provided."", ""Resource"": ""Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M., Carey, L.A., Cortes, J., Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., & Winer, E.P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology, 31, 1623 - 1649."", ""LoE/GoR"": ""Expert opinion/A"", ""Consensus"": ""97%"", ""Type"": ""Guideline statement"", ""Section"": ""General guidelines"", ""unique_id"": ""15eebbed-5855-4757-9bf2-f99936ae8d01""}",guideline
0abdc812-264b-4aa6-aa31-1d58cd1cbace,"Breast tissue is composed of lobules that are glands involved in milk production, ducts that connect the lobules to the nipple and connective tissue, fatty tissue, and lymphatic tissue.","{""Statement"": ""Breast tissue is composed of lobules that are glands involved in milk production, ducts that connect the lobules to the nipple and connective tissue, fatty tissue, and lymphatic tissue."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""0abdc812-264b-4aa6-aa31-1d58cd1cbace""}",statement
168e594e-ddb4-4e13-8a2f-dc8db627ca9b,"Breast cancer occurs when there is an unregulated growth of cells within any of the components of the breast, although this occurs most commonly in the lobules.","{""Statement"": ""Breast cancer occurs when there is an unregulated growth of cells within any of the components of the breast, although this occurs most commonly in the lobules."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""168e594e-ddb4-4e13-8a2f-dc8db627ca9b""}",statement
e21645e5-6184-4c4f-b3fe-c4a2df07ea20,"Although significantly less common, breast cancer can also occur among males.","{""Statement"": ""Although significantly less common, breast cancer can also occur among males."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""e21645e5-6184-4c4f-b3fe-c4a2df07ea20""}",statement
76e75d6e-4a6f-44cb-983a-16ae54dfa837,Breast cancer develops over time and may go through an in situ phase.,"{""Statement"": ""Breast cancer develops over time and may go through an in situ phase."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""76e75d6e-4a6f-44cb-983a-16ae54dfa837""}",statement
014f531c-e16c-41d5-94db-90f23db6bf86,Breast cancer incidence and mortality increase proportionally with age.,"{""Statement"": ""Breast cancer incidence and mortality increase proportionally with age."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""014f531c-e16c-41d5-94db-90f23db6bf86""}",statement
d279b1dc-f2d3-40d5-9fca-1f6506581a11,"Although the overall incidence of breast cancer is slightly lower in black women than in white women, black women have the highest 5 year breast cancer mortality rate for each known stage at diagnosis.","{""Statement"": ""Although the overall incidence of breast cancer is slightly lower in black women than in white women, black women have the highest 5 year breast cancer mortality rate for each known stage at diagnosis."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""d279b1dc-f2d3-40d5-9fca-1f6506581a11""}",statement
3f2c489d-28d5-4c29-830f-34cc9a5f68b5,Younger age at menarche and older age at menopause increases breast cancer risk.,"{""Statement"": ""Younger age at menarche and older age at menopause increases breast cancer risk."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""3f2c489d-28d5-4c29-830f-34cc9a5f68b5""}",statement
9ede0067-e2ac-4ee3-893f-72a76b829984,"Women with a history of breast cancer are at higher risk of developing the disease again, especially if the initial age at diagnosis was less than 40 years of age.","{""Statement"": ""Women with a history of breast cancer are at higher risk of developing the disease again, especially if the initial age at diagnosis was less than 40 years of age."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""9ede0067-e2ac-4ee3-893f-72a76b829984""}",statement
6401208a-41bc-4a49-8b34-7c2f2476a902,"Delayed childbearing, smaller family size, decreased duration of breastfeeding,and hormonal contraceptives have been linked to increased breast cancer risk.","{""Statement"": ""Delayed childbearing, smaller family size, decreased duration of breastfeeding,and hormonal contraceptives have been linked to increased breast cancer risk."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""6401208a-41bc-4a49-8b34-7c2f2476a902""}",statement
4d485afb-dfdf-431a-98b5-e6b2312c09f6,Combined estrogen and progestin therapy increases the risk of developing breast cancer.,"{""Statement"": ""Combined estrogen and progestin therapy increases the risk of developing breast cancer."", ""Resource"": ""Lakshmanaswamy, R. Approaches to Understanding Breast Cancer. First edition. London, United Kingdom: Academic Press is an imprint of Elsevier, 2017. Print."", ""unique_id"": ""4d485afb-dfdf-431a-98b5-e6b2312c09f6""}",statement
5a861681-e266-4f42-ab72-6c4ac540e36a,A33 : A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.,"{""term"": ""A33"", ""url_name"": ""a33"", ""definition"": ""A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/a33"", ""type"": ""cancer_term"", ""unique_id"": ""5a861681-e266-4f42-ab72-6c4ac540e36a""}",cancer_term_definition
286c58a9-bc7f-43bd-8ee6-63e0470b6f78,A6 : A substance being studied in the treatment of cancer. A6 is a small piece of a protein called urokinase (an enzyme that dissolves blood clots or prevents them from forming). It is a type of antiangiogenesis agent and a type of antimetastatic agent. Also called urokinase plasminogen activator (uPA)-derived peptide A6.,"{""term"": ""A6"", ""url_name"": ""a6"", ""definition"": ""A substance being studied in the treatment of cancer. A6 is a small piece of a protein called urokinase (an enzyme that dissolves blood clots or prevents them from forming). It is a type of antiangiogenesis agent and a type of antimetastatic agent. Also called urokinase plasminogen activator (uPA)-derived peptide A6."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/a6"", ""type"": ""cancer_term"", ""unique_id"": ""286c58a9-bc7f-43bd-8ee6-63e0470b6f78""}",cancer_term_definition
8925885a-b49c-4cc6-80df-46d0bdfbe8ed,AAP : An enzyme that is normally found in healthy kidneys. It may be found at high levels in the urine when there are kidney problems.  It is used as a biomarker to detect damage to the kidneys caused by drugs and other agents. It may also be used to diagnose certain kidney and liver disorders. Also called alanine aminopeptidase.,"{""term"": ""AAP"", ""url_name"": ""aap"", ""definition"": ""An enzyme that is normally found in healthy kidneys. It may be found at high levels in the urine when there are kidney problems.  It is used as a biomarker to detect damage to the kidneys caused by drugs and other agents. It may also be used to diagnose certain kidney and liver disorders. Also called alanine aminopeptidase."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/aap"", ""type"": ""cancer_term"", ""unique_id"": ""8925885a-b49c-4cc6-80df-46d0bdfbe8ed""}",cancer_term_definition
74785160-6fbd-4d30-883e-5c6f892220b8,"AAT deficiency : An inherited condition in which the body either does not make enough of a protein called alpha-1 antitrypsin (AAT) or makes an abnormal form of AAT. AAT is made in the liver and helps protect the body’s organs, especially the liver and lungs, from damage. AAT deficiency can lead to serious lung conditions (including emphysema and bronchiectasis) and liver conditions (including cirrhosis, hepatitis, and liver cancer). It may also cause inflammation of the blood vessels and a rare skin condition that causes painful lumps on or under the skin. Lung problems caused by AAT deficiency almost always occur in adults, but liver and skin problems may occur in both adults and children. AAT deficiency is caused by a mutation (change) in a gene called SERPINA1. Also called alpha-1 antitrypsin deficiency.","{""term"": ""AAT deficiency"", ""url_name"": ""aat-deficiency"", ""definition"": ""An inherited condition in which the body either does not make enough of a protein called alpha-1 antitrypsin (AAT) or makes an abnormal form of AAT. AAT is made in the liver and helps protect the body\u2019s organs, especially the liver and lungs, from damage. AAT deficiency can lead to serious lung conditions (including emphysema and bronchiectasis) and liver conditions (including cirrhosis, hepatitis, and liver cancer). It may also cause inflammation of the blood vessels and a rare skin condition that causes painful lumps on or under the skin. Lung problems caused by AAT deficiency almost always occur in adults, but liver and skin problems may occur in both adults and children. AAT deficiency is caused by a mutation (change) in a gene called SERPINA1. Also called alpha-1 antitrypsin deficiency."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/aat-deficiency"", ""type"": ""cancer_term"", ""unique_id"": ""74785160-6fbd-4d30-883e-5c6f892220b8""}",cancer_term_definition
93323bfe-8176-45b9-b131-b7eaa2e9a113,abarelix : A drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called gonadotropin-releasing hormone (GnRH) antagonists. Also called Plenaxis.,"{""term"": ""abarelix"", ""url_name"": ""abarelix"", ""definition"": ""A drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called gonadotropin-releasing hormone (GnRH) antagonists. Also called Plenaxis."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abarelix"", ""type"": ""cancer_term"", ""unique_id"": ""93323bfe-8176-45b9-b131-b7eaa2e9a113""}",cancer_term_definition
d4e47834-d10e-4701-9fe8-37b2db10ac2d,ABCA1 pathway : Describes a group of proteins in a cell that work together to help remove extra cholesterol and certain fats from tissue in the body. Changes in the ABCA1 pathway may lead to diseases of the heart and blood vessels. Drugs or substances that affect this pathway are being studied in the prevention and treatment of some diseases.,"{""term"": ""ABCA1 pathway"", ""url_name"": ""abca1-pathway"", ""definition"": ""Describes a group of proteins in a cell that work together to help remove extra cholesterol and certain fats from tissue in the body. Changes in the ABCA1 pathway may lead to diseases of the heart and blood vessels. Drugs or substances that affect this pathway are being studied in the prevention and treatment of some diseases."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abca1-pathway"", ""type"": ""cancer_term"", ""unique_id"": ""d4e47834-d10e-4701-9fe8-37b2db10ac2d""}",cancer_term_definition
d9ce163c-1e85-429b-9f22-af9d7027b1ea,ABCD rating : A staging system for prostate cancer that uses ABCD. “A” and “B” refer to cancer that is confined to the prostate. “C” refers to cancer that has grown out of the prostate but has not spread to lymph nodes or other places in the body. “D” refers to cancer that has spread to lymph nodes or to other places in the body. Also called Jewett staging system and Whitmore-Jewett staging system.,"{""term"": ""ABCD rating"", ""url_name"": ""abcd-rating"", ""definition"": ""A staging system for prostate cancer that uses ABCD. \u201cA\u201d and \u201cB\u201d refer to cancer that is confined to the prostate. \u201cC\u201d refers to cancer that has grown out of the prostate but has not spread to lymph nodes or other places in the body. \u201cD\u201d refers to cancer that has spread to lymph nodes or to other places in the body. Also called Jewett staging system and Whitmore-Jewett staging system."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abcd-rating"", ""type"": ""cancer_term"", ""unique_id"": ""d9ce163c-1e85-429b-9f22-af9d7027b1ea""}",cancer_term_definition
09e0fd81-9ec4-4b4e-b995-801c8a91e458,"abdomen : The area of the body that contains the pancreas, stomach, intestines, liver, gallbladder, and other organs.","{""term"": ""abdomen"", ""url_name"": ""abdomen"", ""definition"": ""The area of the body that contains the pancreas, stomach, intestines, liver, gallbladder, and other organs."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abdomen"", ""type"": ""cancer_term"", ""unique_id"": ""09e0fd81-9ec4-4b4e-b995-801c8a91e458""}",cancer_term_definition
7a5da3db-4060-4aea-832b-1992892c66e5,"abdominal : Having to do with the abdomen, which is the part of the body between the chest and the hips that contains the pancreas, stomach, intestines, liver, gallbladder, and other organs.","{""term"": ""abdominal"", ""url_name"": ""abdominal"", ""definition"": ""Having to do with the abdomen, which is the part of the body between the chest and the hips that contains the pancreas, stomach, intestines, liver, gallbladder, and other organs."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abdominal"", ""type"": ""cancer_term"", ""unique_id"": ""7a5da3db-4060-4aea-832b-1992892c66e5""}",cancer_term_definition
e3e7b8f1-8119-4896-8564-3d0a43a4fd1f,"abdominal ultrasound : A procedure used to examine the organs in the abdomen. An ultrasound transducer (probe) is pressed firmly against the skin of the abdomen. High-energy sound waves from the transducer bounce off tissues and create echoes. The echoes are sent to a computer, which makes a picture called a sonogram. Also called transabdominal ultrasound.","{""term"": ""abdominal ultrasound"", ""url_name"": ""abdominal-ultrasound"", ""definition"": ""A procedure used to examine the organs in the abdomen. An ultrasound transducer (probe) is pressed firmly against the skin of the abdomen. High-energy sound waves from the transducer bounce off tissues and create echoes. The echoes are sent to a computer, which makes a picture called a sonogram. Also called transabdominal ultrasound."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abdominal-ultrasound"", ""type"": ""cancer_term"", ""unique_id"": ""e3e7b8f1-8119-4896-8564-3d0a43a4fd1f""}",cancer_term_definition
c1b4ae68-515c-4278-9eee-2fd10b6c7d82,"abdominal x-ray : An x-ray of the organs inside the abdomen. An x-ray is a type of radiation that can pass through the body and onto film, making pictures of areas inside the body. X-rays may be used to help diagnose disease.","{""term"": ""abdominal x-ray"", ""url_name"": ""abdominal-x-ray"", ""definition"": ""An x-ray of the organs inside the abdomen. An x-ray is a type of radiation that can pass through the body and onto film, making pictures of areas inside the body. X-rays may be used to help diagnose disease."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abdominal-x-ray"", ""type"": ""cancer_term"", ""unique_id"": ""c1b4ae68-515c-4278-9eee-2fd10b6c7d82""}",cancer_term_definition
34d230c7-8b02-47f7-964c-d19f776593a9,"abdominoperineal resection : Surgery to remove the anus, the rectum, and part of the sigmoid colon through an incision made in the abdomen. The end of the intestine is attached to an opening in the surface of the abdomen and body waste is collected in a disposable bag outside of the body. This opening is called a colostomy. Lymph nodes that contain cancer may also be removed during this operation.","{""term"": ""abdominoperineal resection"", ""url_name"": ""abdominoperineal-resection"", ""definition"": ""Surgery to remove the anus, the rectum, and part of the sigmoid colon through an incision made in the abdomen. The end of the intestine is attached to an opening in the surface of the abdomen and body waste is collected in a disposable bag outside of the body. This opening is called a colostomy. Lymph nodes that contain cancer may also be removed during this operation."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abdominoperineal-resection"", ""type"": ""cancer_term"", ""unique_id"": ""34d230c7-8b02-47f7-964c-d19f776593a9""}",cancer_term_definition
ee84be21-5931-416e-82f5-50a385e59455,"Abecma : A drug used to treat adults with multiple myeloma that relapsed (came back) or did not get better after treatment with at least four other anticancer therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating agent. It is also being studied in the treatment of other types of cancer. Abecma is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Abecma binds to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body’s immune system kill cancer cells. Abecma is a type of CAR T-cell therapy. Also called idecabtagene vicleucel.","{""term"": ""Abecma"", ""url_name"": ""abecma"", ""definition"": ""A drug used to treat adults with multiple myeloma that relapsed (came back) or did not get better after treatment with at least four other anticancer therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating agent. It is also being studied in the treatment of other types of cancer. Abecma is made using a patient\u2019s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Abecma binds to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body\u2019s immune system kill cancer cells. Abecma is a type of CAR T-cell therapy. Also called idecabtagene vicleucel."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abecma"", ""type"": ""cancer_term"", ""unique_id"": ""ee84be21-5931-416e-82f5-50a385e59455""}",cancer_term_definition
384a0d2b-08d1-4a06-8e03-7c6383efd9de,"Abegrin : A substance being studied in the treatment of some types of cancer and other conditions. Abegrin binds to a protein on the surface of blood vessels and may prevent the growth of new blood vessels that tumors need to grow. It may also prevent the spread of cancer. It is a type of antiangiogenesis agent, a type of metastasis inhibitor, and a type of monoclonal antibody. Also called etaracizumab, humanized monoclonal antibody MEDI-522, and MEDI-522.","{""term"": ""Abegrin"", ""url_name"": ""abegrin"", ""definition"": ""A substance being studied in the treatment of some types of cancer and other conditions. Abegrin binds to a protein on the surface of blood vessels and may prevent the growth of new blood vessels that tumors need to grow. It may also prevent the spread of cancer. It is a type of antiangiogenesis agent, a type of metastasis inhibitor, and a type of monoclonal antibody. Also called etaracizumab, humanized monoclonal antibody MEDI-522, and MEDI-522."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abegrin"", ""type"": ""cancer_term"", ""unique_id"": ""384a0d2b-08d1-4a06-8e03-7c6383efd9de""}",cancer_term_definition
199514ae-a7ab-4943-8149-c0f51dda8189,"abemaciclib : A drug used to treat hormone-receptor positive (HR+), HER2-negative (HER2-) breast cancer that is advanced or has spread to other parts of the body. It is used with an aromatase inhibitor in postmenopausal women who have not been treated with hormone therapy. It is used with fulvestrant in women whose disease got worse after treatment with hormone therapy. Abemaciclib is also used alone in men and women whose disease got worse after treatment with hormone therapy and previous chemotherapy. It is also being studied in the treatment of other types of cancer. Abemaciclib blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Also called Verzenio.","{""term"": ""abemaciclib"", ""url_name"": ""abemaciclib"", ""definition"": ""A drug used to treat hormone-receptor positive (HR+), HER2-negative (HER2-) breast cancer that is advanced or has spread to other parts of the body. It is used with an aromatase inhibitor in postmenopausal women who have not been treated with hormone therapy. It is used with fulvestrant in women whose disease got worse after treatment with hormone therapy. Abemaciclib is also used alone in men and women whose disease got worse after treatment with hormone therapy and previous chemotherapy. It is also being studied in the treatment of other types of cancer. Abemaciclib blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Also called Verzenio."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abemaciclib"", ""type"": ""cancer_term"", ""unique_id"": ""199514ae-a7ab-4943-8149-c0f51dda8189""}",cancer_term_definition
38871455-27f8-47ec-aeb6-a6b5709e980c,aberrant crypt foci : Clusters of abnormal tube-like glands in the lining of the colon and rectum. Aberrant crypt foci form before colorectal polyps and are one of the earliest changes that can be seen in the colon that may lead to cancer. Also called ACF.,"{""term"": ""aberrant crypt foci"", ""url_name"": ""aberrant-crypt-foci"", ""definition"": ""Clusters of abnormal tube-like glands in the lining of the colon and rectum. Aberrant crypt foci form before colorectal polyps and are one of the earliest changes that can be seen in the colon that may lead to cancer. Also called ACF."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/aberrant-crypt-foci"", ""type"": ""cancer_term"", ""unique_id"": ""38871455-27f8-47ec-aeb6-a6b5709e980c""}",cancer_term_definition
1fc9af84-a64c-467d-bfc8-876f90acf8fc,"ABI-007 : A form of the anticancer drug paclitaxel that is used alone or with other drugs to treat certain types of breast cancer, non-small cell lung cancer, and pancreatic cancer. ABI-007 may have fewer side effects and work better than other forms of paclitaxel.  It is also being studied in the treatment of other types of cancer.  ABI-007 stops cancer cells from growing and dividing and may kill them.   It is a type of taxane. Also called Abraxane, nanoparticle paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, and protein-bound paclitaxel.","{""term"": ""ABI-007"", ""url_name"": ""abi-007"", ""definition"": ""A form of the anticancer drug paclitaxel that is used alone or with other drugs to treat certain types of breast cancer, non-small cell lung cancer, and pancreatic cancer. ABI-007 may have fewer side effects and work better than other forms of paclitaxel.  It is also being studied in the treatment of other types of cancer.  ABI-007 stops cancer cells from growing and dividing and may kill them.   It is a type of taxane. Also called Abraxane, nanoparticle paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, and protein-bound paclitaxel."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abi-007"", ""type"": ""cancer_term"", ""unique_id"": ""1fc9af84-a64c-467d-bfc8-876f90acf8fc""}",cancer_term_definition
bfc3183c-ebb3-476f-99b1-f947dea988b4,"abiraterone acetate : A drug used with other drugs to treat prostate cancer that has spread to other parts of the body. Abiraterone acetate is used under the brand name Zytiga    to treat patients whose cancer is castration resistant (has not responded to treatments that lower testosterone levels) or whose cancer is high risk and castration sensitive (has responded to treatments that lower testosterone levels). It is also used under the brand name Yonsa to treat patients whose cancer is castration resistant. Abiraterone acetate is also being studied in the treatment of other types of cancer. It lowers the amount of androgens (male hormones), such as testosterone, made by the body. This may stop the growth of cancer cells that need androgens to grow. Abiraterone acetate is a type of antiandrogen.","{""term"": ""abiraterone acetate"", ""url_name"": ""abiraterone-acetate"", ""definition"": ""A drug used with other drugs to treat prostate cancer that has spread to other parts of the body. Abiraterone acetate is used under the brand name Zytiga    to treat patients whose cancer is castration resistant (has not responded to treatments that lower testosterone levels) or whose cancer is high risk and castration sensitive (has responded to treatments that lower testosterone levels). It is also used under the brand name Yonsa to treat patients whose cancer is castration resistant. Abiraterone acetate is also being studied in the treatment of other types of cancer. It lowers the amount of androgens (male hormones), such as testosterone, made by the body. This may stop the growth of cancer cells that need androgens to grow. Abiraterone acetate is a type of antiandrogen."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abiraterone-acetate"", ""type"": ""cancer_term"", ""unique_id"": ""bfc3183c-ebb3-476f-99b1-f947dea988b4""}",cancer_term_definition
33ac813f-d2e9-4f67-b2ce-510aac40a699,"ablation : In medicine, the removal or destruction of a body part or tissue or its function. Ablation may be performed by surgery, hormones, drugs, radiofrequency, heat, or other methods.","{""term"": ""ablation"", ""url_name"": ""ablation"", ""definition"": ""In medicine, the removal or destruction of a body part or tissue or its function. Ablation may be performed by surgery, hormones, drugs, radiofrequency, heat, or other methods."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ablation"", ""type"": ""cancer_term"", ""unique_id"": ""33ac813f-d2e9-4f67-b2ce-510aac40a699""}",cancer_term_definition
81de4164-f839-409c-89cb-83cffa26d793,"abnormal : Not normal. Describes a state, condition, or behavior that is unusual or different from what is considered normal. An abnormal lesion or growth in or on the body may be benign (not cancer), precancerous or premalignant (likely to become cancer), or malignant (cancer).","{""term"": ""abnormal"", ""url_name"": ""abnormal"", ""definition"": ""Not normal. Describes a state, condition, or behavior that is unusual or different from what is considered normal. An abnormal lesion or growth in or on the body may be benign (not cancer), precancerous or premalignant (likely to become cancer), or malignant (cancer)."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abnormal"", ""type"": ""cancer_term"", ""unique_id"": ""81de4164-f839-409c-89cb-83cffa26d793""}",cancer_term_definition
1e80adea-07de-43a2-9c9f-fb63ab3bc9c5,"A-101 Topical Solution : A proprietary topical formulation consisting of a high-concentration of hydrogen peroxide (H2O2), with potential keratolytic activity. Upon administration of the A-101 topical solution to an affected area of skin, the hydrogen peroxide penetrates into the cells, increases oxygen content, produces reactive oxygen species (ROS), causes oxidative stress and induces apoptosis through oxidative damage. This may clear the affected skin cells and remove common warts (verruca vulgaris) or seborrheic keratosis (SK).","{""term"": ""A-101 Topical Solution"", ""name_type"": ""nciConceptName"", ""url_name"": ""a-101-topical-solution"", ""definition"": ""A proprietary topical formulation consisting of a high-concentration of hydrogen peroxide (H2O2), with potential keratolytic activity. Upon administration of the A-101 topical solution to an affected area of skin, the hydrogen peroxide penetrates into the cells, increases oxygen content, produces reactive oxygen species (ROS), causes oxidative stress and induces apoptosis through oxidative damage. This may clear the affected skin cells and remove common warts (verruca vulgaris) or seborrheic keratosis (SK)."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/a33"", ""type"": ""drug_dictionary"", ""unique_id"": ""1e80adea-07de-43a2-9c9f-fb63ab3bc9c5""}",drug_dictionary_definition
afcc6334-22a2-4bf4-a06a-47c15d407ed3,"null : An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist EOS100850 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.","{""term"": ""null"", ""name_type"": ""nciConceptName"", ""url_name"": ""a2a-receptor-antagonist-eos100850"", ""definition"": ""An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist EOS100850 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aap"", ""type"": ""drug_dictionary"", ""unique_id"": ""afcc6334-22a2-4bf4-a06a-47c15d407ed3""}",drug_dictionary_definition
209787ea-5403-4f82-8787-6b86e21bd28f,"A2A/A2B Adenosine Receptor Antagonist INCB106385 : An orally bioavailable antagonist of both the immunomodulatory checkpoint molecules adenosine A2A receptor (A2AR; ADORA2A) and A2B receptor (A2BR; ADORA2B), with potential immunomodulating and antineoplastic activities. Upon oral administration, A2A/A2B adenosine receptor antagonist INCB106385 competes with tumor-released adenosine for binding to A2AR and A2BR expressed on numerous intra-tumoral immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages and T lymphocytes. The binding of INCB106385 to A2AR and A2BR inhibits A2AR/A2BR activity and prevents adenosine-A2AR/A2BR-mediated signaling. A2AR/A2BR inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing. A2AR and A2BR, G protein-coupled signaling receptors, are expressed on the cell surfaces of numerous immune cells. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation.","{""term"": ""A2A/A2B Adenosine Receptor Antagonist INCB106385"", ""name_type"": ""nciConceptName"", ""url_name"": ""a2a-a2b-adenosine-receptor-antagonist-incb106385"", ""definition"": ""An orally bioavailable antagonist of both the immunomodulatory checkpoint molecules adenosine A2A receptor (A2AR; ADORA2A) and A2B receptor (A2BR; ADORA2B), with potential immunomodulating and antineoplastic activities. Upon oral administration, A2A/A2B adenosine receptor antagonist INCB106385 competes with tumor-released adenosine for binding to A2AR and A2BR expressed on numerous intra-tumoral immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages and T lymphocytes. The binding of INCB106385 to A2AR and A2BR inhibits A2AR/A2BR activity and prevents adenosine-A2AR/A2BR-mediated signaling. A2AR/A2BR inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing. A2AR and A2BR, G protein-coupled signaling receptors, are expressed on the cell surfaces of numerous immune cells. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aat-deficiency"", ""type"": ""drug_dictionary"", ""unique_id"": ""209787ea-5403-4f82-8787-6b86e21bd28f""}",drug_dictionary_definition
ce72282e-1a3e-4b0c-897f-31f86bb798f2,"A2AR Antagonist EXS21546 : An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon oral administration, A2AR antagonist EXS21546 selectively targets, binds to and inhibits A2AR expressed on T  lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T lymphocytes. This results in the proliferation and activation of T lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression in the tumor microenvironment (TME). EXS21546 does not penetrate the central nervous system (CNS).
","{""term"": ""A2AR Antagonist EXS21546"", ""name_type"": ""nciConceptName"", ""url_name"": ""a2ar-antagonist-exs21546"", ""definition"": ""An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon oral administration, A2AR antagonist EXS21546 selectively targets, binds to and inhibits A2AR expressed on T  lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T lymphocytes. This results in the proliferation and activation of T lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression in the tumor microenvironment (TME). EXS21546 does not penetrate the central nervous system (CNS).\n"", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abarelix"", ""type"": ""drug_dictionary"", ""unique_id"": ""ce72282e-1a3e-4b0c-897f-31f86bb798f2""}",drug_dictionary_definition
9548ba0f-e62c-45c0-b5a8-2c6e5e1fbd09,"Abacavir Sulfate : A sulfate salt form of abacavir, a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","{""term"": ""Abacavir Sulfate"", ""name_type"": ""nciConceptName"", ""url_name"": ""abacavir-sulfate"", ""definition"": ""A sulfate salt form of abacavir, a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abca1-pathway"", ""type"": ""drug_dictionary"", ""unique_id"": ""9548ba0f-e62c-45c0-b5a8-2c6e5e1fbd09""}",drug_dictionary_definition
1ae808a1-c6ea-41c8-b3c4-8d2959e19710,"Abagovomab : A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.","{""term"": ""Abagovomab"", ""name_type"": ""nciConceptName"", ""url_name"": ""abagovomab"", ""definition"": ""A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abcd-rating"", ""type"": ""drug_dictionary"", ""unique_id"": ""1ae808a1-c6ea-41c8-b3c4-8d2959e19710""}",drug_dictionary_definition
8ad3f5bc-62bb-4373-bc08-58e956293020,"Abaloparatide : A 34 amino acid synthetic analog of human parathyroid hormone-related protein (PTHrP) (PTHrP(1-34) analog), with bone-growing and bone density conserving activities. Upon subcutaneous administration, abaloparatide acts similar to PTHrP and targets, binds to and activates parathyroid hormone 1 (PTH1) receptor (PTH1R), a G protein-coupled receptor (GPCR) expressed in osteoblasts and bone stromal cells. PTH1R activates the cyclic AMP (cAMP) signaling pathway and the bone anabolic signaling pathway, leading to bone growth, increased bone mineral density (BMD) and volume. This correlates with increased bone mass and strength and prevents or treats osteoporosis and decreases fractures.","{""term"": ""Abaloparatide"", ""name_type"": ""nciConceptName"", ""url_name"": ""abaloparatide"", ""definition"": ""A 34 amino acid synthetic analog of human parathyroid hormone-related protein (PTHrP) (PTHrP(1-34) analog), with bone-growing and bone density conserving activities. Upon subcutaneous administration, abaloparatide acts similar to PTHrP and targets, binds to and activates parathyroid hormone 1 (PTH1) receptor (PTH1R), a G protein-coupled receptor (GPCR) expressed in osteoblasts and bone stromal cells. PTH1R activates the cyclic AMP (cAMP) signaling pathway and the bone anabolic signaling pathway, leading to bone growth, increased bone mineral density (BMD) and volume. This correlates with increased bone mass and strength and prevents or treats osteoporosis and decreases fractures."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abdomen"", ""type"": ""drug_dictionary"", ""unique_id"": ""8ad3f5bc-62bb-4373-bc08-58e956293020""}",drug_dictionary_definition
b01860cd-803b-405e-b301-ac99b2d7c7a2,"Abarelix : A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone.  As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.","{""term"": ""Abarelix"", ""name_type"": ""nciConceptName"", ""url_name"": ""abarelix"", ""definition"": ""A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone.  As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abdominal"", ""type"": ""drug_dictionary"", ""unique_id"": ""b01860cd-803b-405e-b301-ac99b2d7c7a2""}",drug_dictionary_definition
2fbe40db-a43a-4d50-aaf0-2aeaa758a227,"Abatacept : A soluble fusion protein consisting of the extracellular
domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to
a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1
(IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","{""term"": ""Abatacept"", ""name_type"": ""nciConceptName"", ""url_name"": ""abatacept"", ""definition"": ""A soluble fusion protein consisting of the extracellular\ndomain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to\na modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1\n(IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abdominal-ultrasound"", ""type"": ""drug_dictionary"", ""unique_id"": ""2fbe40db-a43a-4d50-aaf0-2aeaa758a227""}",drug_dictionary_definition
0e705b67-650e-4e2e-b1c2-fb7f2485f36c,"Losatuxizumab Vedotin : An intravenously-administered agent capable of modulating the activity of epidermal growth factor receptor (EGFR), with potential antineoplastic activity.","{""term"": ""Losatuxizumab Vedotin"", ""name_type"": ""nciConceptName"", ""url_name"": ""losatuxizumab-vedotin"", ""definition"": ""An intravenously-administered agent capable of modulating the activity of epidermal growth factor receptor (EGFR), with potential antineoplastic activity."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abdominal-x-ray"", ""type"": ""drug_dictionary"", ""unique_id"": ""0e705b67-650e-4e2e-b1c2-fb7f2485f36c""}",drug_dictionary_definition
33eb2816-57d7-45ce-9046-9fe1e0de7c8b,"Abemaciclib : An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","{""term"": ""Abemaciclib"", ""name_type"": ""nciConceptName"", ""url_name"": ""abemaciclib"", ""definition"": ""An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abemaciclib"", ""type"": ""drug_dictionary"", ""unique_id"": ""33eb2816-57d7-45ce-9046-9fe1e0de7c8b""}",drug_dictionary_definition
6e34b477-2dae-42d5-b43e-548925f7cb85,"Abequolixron : An orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, abequolixron selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels.","{""term"": ""Abequolixron"", ""name_type"": ""nciConceptName"", ""url_name"": ""abequolixron"", ""definition"": ""An orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, abequolixron selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aberrant-crypt-foci"", ""type"": ""drug_dictionary"", ""unique_id"": ""6e34b477-2dae-42d5-b43e-548925f7cb85""}",drug_dictionary_definition
080c29d9-ba55-485f-b7ee-1f61d8dbbd37,"Abexinostat Tosylate : The tosylate salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.","{""term"": ""Abexinostat Tosylate"", ""name_type"": ""nciConceptName"", ""url_name"": ""abexinostat-tosylate"", ""definition"": ""The tosylate salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abiraterone-acetate"", ""type"": ""drug_dictionary"", ""unique_id"": ""080c29d9-ba55-485f-b7ee-1f61d8dbbd37""}",drug_dictionary_definition
b8960621-21f8-4945-82dd-73caaa81e7d0,"Abiraterone Acetate : An orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.
","{""term"": ""Abiraterone Acetate"", ""name_type"": ""nciConceptName"", ""url_name"": ""abiraterone-acetate"", ""definition"": ""An orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.\n"", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ablation"", ""type"": ""drug_dictionary"", ""unique_id"": ""b8960621-21f8-4945-82dd-73caaa81e7d0""}",drug_dictionary_definition
da869a0d-7211-4a9b-9d5e-07f8c099c389,"Abiraterone Amorphous Solid Dispersion Formulation DST-2970 : An orally bioavailable, amorphous solid dispersion formulation of the steroidal compound abiraterone, with potential antiandrogen activity. Upon oral administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","{""term"": ""Abiraterone Amorphous Solid Dispersion Formulation DST-2970"", ""name_type"": ""nciConceptName"", ""url_name"": ""abiraterone-amorphous-solid-dispersion-formulation-dst-2970"", ""definition"": ""An orally bioavailable, amorphous solid dispersion formulation of the steroidal compound abiraterone, with potential antiandrogen activity. Upon oral administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This may suppress testosterone production by both the testes and the adrenals to castrate-range levels."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug"", ""url"": ""https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abnormal"", ""type"": ""drug_dictionary"", ""unique_id"": ""da869a0d-7211-4a9b-9d5e-07f8c099c389""}",drug_dictionary_definition
6b45e32f-3962-47c9-90cf-dd692471deaa,"acrochordon : A small, benign skin growth that may have a stalk (peduncle). Acrochordons most commonly appear on the neck, axillary, groin, and inframammary regions. Also called skin tag.","{""term"": ""acrochordon"", ""url_name"": ""acrochordon"", ""definition"": ""A small, benign skin growth that may have a stalk (peduncle). Acrochordons most commonly appear on the neck, axillary, groin, and inframammary regions. Also called skin tag."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/acrochordon"", ""type"": ""genetics_term"", ""unique_id"": ""6b45e32f-3962-47c9-90cf-dd692471deaa""}",genetics_term_definition
e35ebfde-5e6f-4831-9253-14feca2db48b,admixture mapping : A method used to identify genetic variants associated with traits and/or diseases in ethnic groups whose genomes resulted from a recent mixture of two or more geographically distinct ancestral populations.,"{""term"": ""admixture mapping"", ""url_name"": ""admixture-mapping"", ""definition"": ""A method used to identify genetic variants associated with traits and/or diseases in ethnic groups whose genomes resulted from a recent mixture of two or more geographically distinct ancestral populations."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/admixture-mapping"", ""type"": ""genetics_term"", ""unique_id"": ""e35ebfde-5e6f-4831-9253-14feca2db48b""}",genetics_term_definition
6b80d3a4-4005-4fe5-8b73-2af7beec9eee,"affected individual : In genetics, describes an individual who has a particular phenotypic trait or disease. The individual expresses the trait or has signs and symptoms of the disease.","{""term"": ""affected individual"", ""url_name"": ""affected-individual"", ""definition"": ""In genetics, describes an individual who has a particular phenotypic trait or disease. The individual expresses the trait or has signs and symptoms of the disease."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/affected-individual"", ""type"": ""genetics_term"", ""unique_id"": ""6b80d3a4-4005-4fe5-8b73-2af7beec9eee""}",genetics_term_definition
3a33b9b9-5b54-4039-b607-1cb6c8ebee1d,"allele : One of two or more DNA sequences occurring at a particular gene locus. Typically one allele (“normal” DNA sequence) is common, and other alleles (mutations) are rare.","{""term"": ""allele"", ""url_name"": ""allele"", ""definition"": ""One of two or more DNA sequences occurring at a particular gene locus. Typically one allele (\u201cnormal\u201d DNA sequence) is common, and other alleles (mutations) are rare."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/allele"", ""type"": ""genetics_term"", ""unique_id"": ""3a33b9b9-5b54-4039-b607-1cb6c8ebee1d""}",genetics_term_definition
2a5edb62-cecc-443e-bcb2-a7dc9ef0b0f4,allelic heterogeneity : The presence of different variants at a single gene locus that cause the same or similar phenotypic expressions of a disease or condition.,"{""term"": ""allelic heterogeneity"", ""url_name"": ""allelic-heterogeneity"", ""definition"": ""The presence of different variants at a single gene locus that cause the same or similar phenotypic expressions of a disease or condition."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/allelic-heterogeneity"", ""type"": ""genetics_term"", ""unique_id"": ""2a5edb62-cecc-443e-bcb2-a7dc9ef0b0f4""}",genetics_term_definition
4b48012d-e162-487e-849c-c92004001665,"aneuploidy : The occurrence of one or more extra or missing chromosomes leading to an unbalanced chromosome complement, or any chromosome number that is not an exact multiple of the haploid number (which is 23).","{""term"": ""aneuploidy"", ""url_name"": ""aneuploidy"", ""definition"": ""The occurrence of one or more extra or missing chromosomes leading to an unbalanced chromosome complement, or any chromosome number that is not an exact multiple of the haploid number (which is 23)."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/aneuploidy"", ""type"": ""genetics_term"", ""unique_id"": ""4b48012d-e162-487e-849c-c92004001665""}",genetics_term_definition
2cf74d14-13ff-4451-9b0d-aa386559624a,"antioncogene : A type of gene that regulates cell growth. When an antioncogene is mutated, uncontrolled cell growth may occur. This may contribute to the development of cancer. Also called tumor suppressor gene.","{""term"": ""antioncogene"", ""url_name"": ""antioncogene"", ""definition"": ""A type of gene that regulates cell growth. When an antioncogene is mutated, uncontrolled cell growth may occur. This may contribute to the development of cancer. Also called tumor suppressor gene."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/antioncogene"", ""type"": ""genetics_term"", ""unique_id"": ""2cf74d14-13ff-4451-9b0d-aa386559624a""}",genetics_term_definition
6b2e9ff0-cd52-4c92-b865-e8218bf7c0cc,"ART : Procedures that use donor or nondonor eggs and sperm to create embryos in vitro. Examples of ART include in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). These procedures may be used prior to preimplantation genetic testing (PGT).
 Also called assisted reproductive technology.","{""term"": ""ART"", ""url_name"": ""art"", ""definition"": ""Procedures that use donor or nondonor eggs and sperm to create embryos in vitro. Examples of ART include in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). These procedures may be used prior to preimplantation genetic testing (PGT).\n Also called assisted reproductive technology."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/art"", ""type"": ""genetics_term"", ""unique_id"": ""6b2e9ff0-cd52-4c92-b865-e8218bf7c0cc""}",genetics_term_definition
6af7653c-d588-465c-8131-36da0b06ebf2,"Ashkenazi Jews : One of two
          major ancestral groups of Jewish individuals, comprised of
          those whose ancestors lived in Central and Eastern Europe
          (e.g., Germany, Poland, Russia). The other group is
          designated Sephardic Jews and includes those whose
          ancestors lived in North Africa, the Middle East, and
          Spain. Most Jews living in the United States are of
          Ashkenazi descent.","{""term"": ""Ashkenazi Jews"", ""url_name"": ""ashkenazi-jews"", ""definition"": ""One of two\n          major ancestral groups of Jewish individuals, comprised of\n          those whose ancestors lived in Central and Eastern Europe\n          (e.g., Germany, Poland, Russia). The other group is\n          designated Sephardic Jews and includes those whose\n          ancestors lived in North Africa, the Middle East, and\n          Spain. Most Jews living in the United States are of\n          Ashkenazi descent."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/ashkenazi-jews"", ""type"": ""genetics_term"", ""unique_id"": ""6af7653c-d588-465c-8131-36da0b06ebf2""}",genetics_term_definition
6677ca2d-4380-4321-9288-3794363d5f98,"assisted reproductive technology : Procedures that use donor or nondonor eggs and sperm to create embryos in vitro. Examples of assisted reproductive technology include in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). These procedures may be used prior to preimplantation genetic testing (PGT).
 Also called ART.","{""term"": ""assisted reproductive technology"", ""url_name"": ""assisted-reproductive-technology"", ""definition"": ""Procedures that use donor or nondonor eggs and sperm to create embryos in vitro. Examples of assisted reproductive technology include in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). These procedures may be used prior to preimplantation genetic testing (PGT).\n Also called ART."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/assisted-reproductive-technology"", ""type"": ""genetics_term"", ""unique_id"": ""6677ca2d-4380-4321-9288-3794363d5f98""}",genetics_term_definition
abb94877-27bf-42fb-acda-7f27f071f453,"attributable risk : Proportion of a disease in exposed individuals that can be attributed to an exposure. In the context of genetic studies, the ""exposure"" is the frequency of a specific genetic variant.","{""term"": ""attributable risk"", ""url_name"": ""attributable-risk"", ""definition"": ""Proportion of a disease in exposed individuals that can be attributed to an exposure. In the context of genetic studies, the \""exposure\"" is the frequency of a specific genetic variant."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/attributable-risk"", ""type"": ""genetics_term"", ""unique_id"": ""abb94877-27bf-42fb-acda-7f27f071f453""}",genetics_term_definition
141a4304-6dde-443a-ad69-cd264a78f911,autosomal : Having to do with any of the 22 numbered pairs of chromosomes found in most human cells. Autosomal chromosomes are numbered 1-22. The sex chromosomes (X and Y chromosomes) determine whether an individual is male or female and are not considered autosomal chromosomes.,"{""term"": ""autosomal"", ""url_name"": ""autosomal"", ""definition"": ""Having to do with any of the 22 numbered pairs of chromosomes found in most human cells. Autosomal chromosomes are numbered 1-22. The sex chromosomes (X and Y chromosomes) determine whether an individual is male or female and are not considered autosomal chromosomes."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/autosomal"", ""type"": ""genetics_term"", ""unique_id"": ""141a4304-6dde-443a-ad69-cd264a78f911""}",genetics_term_definition
e9495ce8-6772-4b25-a284-63dfeb13a38e,"autosomal dominant inheritance : One of the ways a genetic trait or a genetic condition can be inherited. In autosomal dominant inheritance, a genetic condition occurs when a variant is present in only one allele (copy) of a given gene. 
","{""term"": ""autosomal dominant inheritance"", ""url_name"": ""autosomal-dominant-inheritance"", ""definition"": ""One of the ways a genetic trait or a genetic condition can be inherited. In autosomal dominant inheritance, a genetic condition occurs when a variant is present in only one allele (copy) of a given gene. \n"", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/autosomal-dominant-inheritance"", ""type"": ""genetics_term"", ""unique_id"": ""e9495ce8-6772-4b25-a284-63dfeb13a38e""}",genetics_term_definition
eeb0cde9-2006-411e-b668-bc97e6ba282c,"autosomal recessive inheritance : One of the ways a genetic trait or a genetic condition can be inherited. In autosomal recessive inheritance, a genetic condition occurs when one variant is present on both alleles (copies) of a given gene. 
","{""term"": ""autosomal recessive inheritance"", ""url_name"": ""autosomal-recessive-inheritance"", ""definition"": ""One of the ways a genetic trait or a genetic condition can be inherited. In autosomal recessive inheritance, a genetic condition occurs when one variant is present on both alleles (copies) of a given gene. \n"", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/autosomal-recessive-inheritance"", ""type"": ""genetics_term"", ""unique_id"": ""eeb0cde9-2006-411e-b668-bc97e6ba282c""}",genetics_term_definition
0d97ea99-12c3-4cfa-a32e-ca0ad7e5ee61,"band : When chromosomes at a particular stage in cell division are stained using one of several laboratory techniques, a specific pattern of light and dark stripes (bands) appears when the chromosomes are viewed through a microscope; the banding pattern assists in assigning each chromosome its particular number and evaluating its structure.","{""term"": ""band"", ""url_name"": ""band"", ""definition"": ""When chromosomes at a particular stage in cell division are stained using one of several laboratory techniques, a specific pattern of light and dark stripes (bands) appears when the chromosomes are viewed through a microscope; the banding pattern assists in assigning each chromosome its particular number and evaluating its structure."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/band"", ""type"": ""genetics_term"", ""unique_id"": ""0d97ea99-12c3-4cfa-a32e-ca0ad7e5ee61""}",genetics_term_definition
5e732172-5b23-4040-8138-46eaa4175500,"base pair : Two nitrogen-containing bases (or nucleotides) that pair together to form the structure of DNA. The four bases in DNA are adenine (A), cytosine (C), guanine (G), and thymine (T). These bases form specific pairs (A with T, and G with C). Base pair may also refer to the actual number of base pairs, such as 8 base pairs, in a sequence of nucleotides.","{""term"": ""base pair"", ""url_name"": ""base-pair"", ""definition"": ""Two nitrogen-containing bases (or nucleotides) that pair together to form the structure of DNA. The four bases in DNA are adenine (A), cytosine (C), guanine (G), and thymine (T). These bases form specific pairs (A with T, and G with C). Base pair may also refer to the actual number of base pairs, such as 8 base pairs, in a sequence of nucleotides."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/base-pair"", ""type"": ""genetics_term"", ""unique_id"": ""5e732172-5b23-4040-8138-46eaa4175500""}",genetics_term_definition
e1162914-fa13-4463-a614-5db0328452f2,"biallelic : Of or
          pertaining to both alleles of a single gene (paternal and
          maternal). For example, biallelic mutation carriers have a
          mutation (not necessarily the same mutation) in both copies
          of a particular gene (a paternal and a maternal
          mutation).","{""term"": ""biallelic"", ""url_name"": ""biallelic"", ""definition"": ""Of or\n          pertaining to both alleles of a single gene (paternal and\n          maternal). For example, biallelic mutation carriers have a\n          mutation (not necessarily the same mutation) in both copies\n          of a particular gene (a paternal and a maternal\n          mutation)."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/biallelic"", ""type"": ""genetics_term"", ""unique_id"": ""e1162914-fa13-4463-a614-5db0328452f2""}",genetics_term_definition
eb20f893-5fec-40d5-bd3f-80698ec6d97c,"carrier : In classical genetics, an individual who carries one deleterious allele for an autosomal recessive disorder. In clinical discussions, may refer to an individual who carries a deleterious allele that predisposes to disease.","{""term"": ""carrier"", ""url_name"": ""carrier"", ""definition"": ""In classical genetics, an individual who carries one deleterious allele for an autosomal recessive disorder. In clinical discussions, may refer to an individual who carries a deleterious allele that predisposes to disease."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/carrier"", ""type"": ""genetics_term"", ""unique_id"": ""eb20f893-5fec-40d5-bd3f-80698ec6d97c""}",genetics_term_definition
00cfd76f-9b3e-4d45-956d-a87cb60c1e2d,"carrier frequency : The proportion of individuals in a population who have a single copy of a specific recessive genetic variant. Carrier frequency also sometimes refers to the prevalence of variants in dominantly acting genes, such as BRCA1 and BRCA2. Also called carrier rate.","{""term"": ""carrier frequency"", ""url_name"": ""carrier-frequency"", ""definition"": ""The proportion of individuals in a population who have a single copy of a specific recessive genetic variant. Carrier frequency also sometimes refers to the prevalence of variants in dominantly acting genes, such as BRCA1 and BRCA2. Also called carrier rate."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/carrier-frequency"", ""type"": ""genetics_term"", ""unique_id"": ""00cfd76f-9b3e-4d45-956d-a87cb60c1e2d""}",genetics_term_definition
ae7b135f-4983-41b1-b7dd-f2607de9995e,"carrier rate : The proportion of individuals in a population who have a single copy of a specific recessive genetic variant. Carrier rate also sometimes refers to the prevalence of variants in dominantly acting genes, such as BRCA1 and BRCA2. Also called carrier frequency.","{""term"": ""carrier rate"", ""url_name"": ""carrier-rate"", ""definition"": ""The proportion of individuals in a population who have a single copy of a specific recessive genetic variant. Carrier rate also sometimes refers to the prevalence of variants in dominantly acting genes, such as BRCA1 and BRCA2. Also called carrier frequency."", ""resource"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary"", ""url"": ""https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/carrier-rate"", ""type"": ""genetics_term"", ""unique_id"": ""ae7b135f-4983-41b1-b7dd-f2607de9995e""}",genetics_term_definition
